Celldex’s CSU drug could challenge a Novartis candidate after PhII
26 Feb 2024
Phase 2Clinical Result
Celldex Therapeutics’ anti-KIT antibody hit the primary endpoint in a mid-stage test in chronic spontaneous urticaria, with some analysts describing the data as better than a Novartis therapy that’s further ahead in development.
Celldex’s Phase II trial set three doses of barzolvolimab against placebo in 208 patients with chronic spontaneous urticaria (CSU) who were symptomatic despite antihistamine treatment, including some who were refractory to biologics such as Novartis and Genentech’s Xolair. There are currently no approved treatments for patients whose disease is not controlled by Xolair.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.